Folker Wenzel

Folker Wenzel

Auto-generated profile, based on publicly available information

Folker Wenzel

From the Institute for Transplantation Diagnostics and Cell Therapy, University of Duesseldorf, Duesseldorf, Germany; Blood Donation Service Munich, Germany; Hospital Laboratory Network Brandenburg‐Berlin, Germany; Institute of Haemostaseology and Transfusion Medicine, University of Duesseldorf; Frauenklinik Inselspital Bern University Hospital; and Medical Faculty Heinrich Heine University Duesseldorf, Duesseldorf, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2011 in Transfusion
Verified
Journal Article
Closed access
PDF file
JFJohannes Christian Fischer
Johannes Christian Fischer
EQErnst M. Quenzel
Ernst M. Quenzel
RMRainer Moog
Rainer Moog
FWFolker Wenzel
Folker Wenzel
RRRegina Riethmacher
Regina Riethmacher
GGGünther Giers
Günther Giers

1 January 2010 in Clinical Hemorheology and Microcirculation
Verified
Journal Article
Closed access
FWFolker Wenzel
Folker Wenzel
WGWolfgang Gruber
Wolfgang Gruber
GGGünther Giers
Günther Giers
Thrombocytopenia is commonly observed during interferon-α (IFN-α) therapy in patients with chronic hepatitis C. Since thrombopoietin (TPO) is the main regulator of thrombopoiesis, thrombocytopenia may partially be due to a reduced TPO generation. Because of the developments of the second generation of TPO mimetic drugs patients with reduced TPO levels should be identified possibly having a benefit by medicinal stimulation of thrombopoiesis. Therefore, platelet count and serum TPO concentration of patients receiving an interferon-α therapy were determined. Twelve patients treated with IFN-α (daily 10×106 IU s.c. for four weeks) in cause of chronic hepatitis C were examined during the first month of therapy. Serum TPO concentration significantly decreased from 80.8±48.0 to 34.6±24.5 pg/ml (p<0.05, Mann–Whitney test), and platelet count declined from 214,417±48,292 to 151,333±44,726 platelets/μl. During the following three weeks platelet count remained at a low level, while serum TPO increased to normal range. In conclusion, an interferon treatment causes reduced serum TPO level during the first week of therapy accompanied by decreased platelet count. The reduction in TPO synthesis contributes to the development of thrombocytopenia in patients during interferon therapy.